睿知中国医院研究地图
候选清单

正在招募乳腺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07441460,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed invasive breast cancer.

    入选标准第 4 条

    Pathologically confirmed positive regional lymph nodes.

    入选标准第 6 条

  3. Female participants of childbearing potential must have a negative blood pregnancy test result within 7 days prior to randomization, and agree to use reliable and effective contraception during the study treatment period and for 7 months after the last dose of study treatment. Male participants with female partners of childbearing potential must agree to use reliable and effective contraception during the study treatment period and for 7 months after the last dose of study treatment.

    入选标准第 16 条

    Prior systemic chemotherapy, endocrine therapy, anti-HER2 targeted therapy, or local radiotherapy for breast cancer.

    排除标准第 3 条

    Use of strong CYP3A4 inhibitors within 14 days prior to randomization or planned use during the combination chemotherapy period.

    排除标准第 4 条

  4. ECOG performance status score of 0 or 1.

    入选标准第 3 条

  5. Absolute neutrophil count ≥ 1.5 × 10⁹/L

    入选标准第 9 条

    Platelet count ≥ 100 × 10⁹/L

    入选标准第 10 条

    Hemoglobin ≥ 90 g/L

    入选标准第 11 条

    Liver function: Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for participants with Gilbert's syndrome); ALT and AST ≤ 2.5 × ULN; Alkaline phosphatase ≤ 2.5 × ULN

    入选标准第 12 条

    Coagulation function: INR ≤ 1.5 × ULN and aPTT ≤ 1.5 × ULN

    入选标准第 13 条

    Renal function: Creatinine clearance ≥ 50 mL/min

    入选标准第 14 条

  6. History of other malignancy within 5 years prior to randomization, except for the breast cancer under study and locally curable malignancies treated with curative intent.

    排除标准第 2 条

  7. Pregnant or lactating women.

    排除标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07441460,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntarily participate and sign the informed consent form.
  2. Age ≥ 18 years.
  3. ECOG performance status score of 0 or 1.
  4. Histologically or cytologically confirmed invasive breast cancer.
  5. Must have undergone prior radical mastectomy or breast-conserving surgery for breast cancer.
  6. Pathologically confirmed positive regional lymph nodes.
  7. Tumor tissue confirmed as HER2-positive by the local laboratory.
  8. Adequate organ and bone marrow function:
  9. Absolute neutrophil count ≥ 1.5 × 10⁹/L
  10. Platelet count ≥ 100 × 10⁹/L
  11. Hemoglobin ≥ 90 g/L
  12. Liver function: Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for participants with Gilbert's syndrome); ALT and AST ≤ 2.5 × ULN; Alkaline phosphatase ≤ 2.5 × ULN
  13. Coagulation function: INR ≤ 1.5 × ULN and aPTT ≤ 1.5 × ULN
  14. Renal function: Creatinine clearance ≥ 50 mL/min
  15. LVEF ≥ 55%
  16. Female participants of childbearing potential must have a negative blood pregnancy test result within 7 days prior to randomization, and agree to use reliable and effective contraception during the study treatment period and for 7 months after the last dose of study treatment. Male participants with female partners of childbearing potential must agree to use reliable and effective contraception during the study treatment period and for 7 months after the last dose of study treatment.

排除标准:Exclusion Criteria:

  1. History of any prior ipsilateral and/or contralateral invasive breast cancer.
  2. History of other malignancy within 5 years prior to randomization, except for the breast cancer under study and locally curable malignancies treated with curative intent.
  3. Prior systemic chemotherapy, endocrine therapy, anti-HER2 targeted therapy, or local radiotherapy for breast cancer.
  4. Use of strong CYP3A4 inhibitors within 14 days prior to randomization or planned use during the combination chemotherapy period.
  5. Known contraindication to any study drug or history of hypersensitivity to any component or known excipient of the study drugs.
  6. Significant cardiovascular disease history, including: prior coronary artery bypass graft or coronary stenting; myocardial infarction or cerebrovascular accident within 6 months prior to randomization; history of congestive heart failure/systolic dysfunction (LVEF < 50%) or unstable angina; history of clinically significant prolonged QT interval or QTcF (Fridericia) > 450 ms at screening; uncontrolled severe hypertension (systolic BP > 180 mmHg and/or diastolic BP > 100 mmHg); high-risk arrhythmias [e.g., atrial tachycardia with resting heart rate ≥ 100 bpm, significant ventricular arrhythmia (ventricular tachycardia), or high-grade atrioventricular block (Mobitz type II second-degree or third-degree AV block)].
  7. Severe chronic or active infection requiring intravenous anti-infective therapy within 14 days prior to randomization.
  8. Participation in another interventional clinical trial within 4 weeks prior to randomization.
  9. Pregnant or lactating women.
  10. Any other condition that may interfere with the participant's ability to comply with study procedures, may not be in the participant's best interest to participate, or may affect study results (e.g., history of neurological or psychiatric disorders, alcohol or drug abuse, or any other clinically significant disease or condition).

引自 ClinicalTrials.gov, NCT07441460, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07441460,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07441460